Imaging vascular properties of pediatric brain tumors using ferumoxytol and gadolinium in a single imaging session; an NCI-sponsored exploratory trial (code 7228) (NCT00978562)73 | 0 | To assess the safety and effectiveness of ferumoxytol in improving the ability to image pediatric brain tumors |
MRI using ferumoxytol in patients with primary brain cancer or brain metastases from lung or breast cancer; an NCI-sponsored multidisciplinary study (NCT00103038)74 | 2 | Characterization of vascular properties of tumors in the CNS using ferumoxytol for dynamic-susceptibility contrast MRI to compare with those obtained using a gadolinium-based contrast agent for dynamic contrast-enhanced imaging in a single MR imaging session; imaging properties will be assessed longitudinally with up to 6 imaging sessions for 2 years |
Magnetic resonance (MR) imaging study using ferumoxytol to assess early tumor response in patients with glioblastoma multiforme (code 7228) (NCT00660543)75 | 1 | Evaluating the ability of ferumoxytol to assess effective early treatment response in glioblastoma multiforme using dynamic perfusion, BBB permeability measurement |
Ferumoxytol and gadolinium magnetic resonance imaging (MRI) at 3T and 7T in patients with malignant brain tumors (NCT00659126)76 | 2 | Comparing dynamic perfusion, BBB permeability measurement in 2 different magnetic fields (3T and 7T) in the evaluation of brain tumors; gadolinium and ferumoxytol will be used as contrast agents |
Assessing dynamic magnetic resonance (MR) imaging in patients with recurrent high grade glioma receiving chemotherapy (code 7228) (NCT00769093)77 | 1 | Evaluation of imaging changes induced by bevacizumab with dexamethasone in patients with high-grade glioma |
MR, histologic and EM imaging of intravenous ferumoxytol in central nervous system (CNS) inflammation (NCT00659776)78 | 2 | Evaluation of the safety and efficacy of ferumoxytol |